BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
BioCentury | Dec 22, 2014
Company News

Stanford University inflammation news

Silicon Valley entrepreneur Sean Parker pledged $24 million over the next two years to establish a research center at the Stanford University School of Medicine that aims to discover lasting cures for allergies. The Sean...
BioCentury | Jun 18, 2012
Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc. 's relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway...
BioCentury | Feb 25, 2010
Cover Story

Cholesterol metabolism ADds up

Reports by independent teams at Dartmouth College and Albert Einstein College of Medicine of Yeshiva University suggest that blocking production and transport of cholesteryl esters, the extracellular form of cholesterol, could be useful for treating...
BioCentury | Nov 4, 2002
Company News

Genome Therapeutics Inc., Interlink Biotechnologies LLC deal

...Interlink for cell-based screening to discover anti-infectives. The companies will collaborate on developing identified leads. Interlink...
...use of resulting products in the areas of anti-infectives. Genome Therapeutics Inc. (GENE), Waltham, Mass. Interlink Biotechnologies...
BioCentury | Oct 28, 2002
Company News

Interlink, GENE anti-infective screening deal

...Genome Therapeutics (GENE) will receive access to libraries of natural products from Interlink (Princeton, N.J.) for...
...N.J.) for cell-based screening to discover anti-infectives. The companies will collaborate on developing identified leads. Interlink...
BioCentury | May 13, 2002
Company News

InterLink Biotechnologies LLC, Virtual Drug Discovery Inc., Wyeth deal

...Virtual Drug will access InterLink's IP and expertise related to peptides that have increased stability and...
...access fees to InterLink, which will be eligible for milestones and royalties on resulting products. InterLink...
...is eligible for royalties. Separately, WYE's Fort Dodge Animal Health division (Overland, Kan.) will access InterLink's...
BioCentury | May 14, 2001
Politics, Policy & Law

Read for free

September 2001 could mark the beginning of a fundamental restructuring of the relationship between scientists and the institutions that publish their research, as well as the start of an era in which scientific information is...
BioCentury | Feb 14, 2000
Company News

InterLink Biotechnologies LLC, Darwich Asociados deal

...The companies created InterLink Sur Biotecnologias, a 50-50 joint venture, to provide agronomic and soil testing...
...producers interested in selling genetically modified (GM) crops for export or in producing GM-free crops. InterLink Biotechnologies...
Items per page:
1 - 10 of 16
BioCentury | Jul 25, 2020
Product Development

NIH, HHS fast-tracking point-of-care, pooled tech as way out of testing crunch

The U.S. government is taking non-conventional paths to point-of-care and pooled technologies in its push to bulk up and speed up the country’s strained COVID-19 testing capacity. In HHS’s case, the department is scrambling to...
BioCentury | Jun 2, 2016
Product R&D

Local reagent makes good

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting...
BioCentury | Dec 22, 2014
Company News

Stanford University inflammation news

Silicon Valley entrepreneur Sean Parker pledged $24 million over the next two years to establish a research center at the Stanford University School of Medicine that aims to discover lasting cures for allergies. The Sean...
BioCentury | Jun 18, 2012
Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc. 's relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway...
BioCentury | Feb 25, 2010
Cover Story

Cholesterol metabolism ADds up

Reports by independent teams at Dartmouth College and Albert Einstein College of Medicine of Yeshiva University suggest that blocking production and transport of cholesteryl esters, the extracellular form of cholesterol, could be useful for treating...
BioCentury | Nov 4, 2002
Company News

Genome Therapeutics Inc., Interlink Biotechnologies LLC deal

...Interlink for cell-based screening to discover anti-infectives. The companies will collaborate on developing identified leads. Interlink...
...use of resulting products in the areas of anti-infectives. Genome Therapeutics Inc. (GENE), Waltham, Mass. Interlink Biotechnologies...
BioCentury | Oct 28, 2002
Company News

Interlink, GENE anti-infective screening deal

...Genome Therapeutics (GENE) will receive access to libraries of natural products from Interlink (Princeton, N.J.) for...
...N.J.) for cell-based screening to discover anti-infectives. The companies will collaborate on developing identified leads. Interlink...
BioCentury | May 13, 2002
Company News

InterLink Biotechnologies LLC, Virtual Drug Discovery Inc., Wyeth deal

...Virtual Drug will access InterLink's IP and expertise related to peptides that have increased stability and...
...access fees to InterLink, which will be eligible for milestones and royalties on resulting products. InterLink...
...is eligible for royalties. Separately, WYE's Fort Dodge Animal Health division (Overland, Kan.) will access InterLink's...
BioCentury | May 14, 2001
Politics, Policy & Law

Read for free

September 2001 could mark the beginning of a fundamental restructuring of the relationship between scientists and the institutions that publish their research, as well as the start of an era in which scientific information is...
BioCentury | Feb 14, 2000
Company News

InterLink Biotechnologies LLC, Darwich Asociados deal

...The companies created InterLink Sur Biotecnologias, a 50-50 joint venture, to provide agronomic and soil testing...
...producers interested in selling genetically modified (GM) crops for export or in producing GM-free crops. InterLink Biotechnologies...
Items per page:
1 - 10 of 16